Savara Pharmaceuticals needed several million dollars to take its inhalable drug for troublesome infections in cystic fibrosis patients through Phase 2 clinical trials. So CEO Rob Neville, naturally, began talking with venture capitalists. But in the end, he didn’t end up needing any of their money.
Over the course of about a year, Savara raised a $16 million Series B round – in two tranches – led by a quartet of angel groups from central Texas to southern California.
{iframe}http://medcitynews.com/2013/06/success-with-an-angel-syndicate-how-one-pharma-startup-raised-16m-without-vcs/{/iframe}